Read on Twitter
$ibio is an innovator biologics company developing therapeutics and vaccines for the betterment of human and animal health, including a virus-like particle (VLP) -based vaccine against SARS-CoV-2. iBio’s subsidiary, iBio CDMO is a global leader in plant-based manufacturing.
It’s FastPharming® and FastGlycaneering™ platforms provide contract development and manufacturing services via its 130,000 square foot facility in Bryan, Texas. The speed and scalability of FastPharming make it an ideal choice for other innovator companies who want to -
- rapidly produce COVID-19 biologics.
https://www.ibioinc.com
https://www.ibioinc.com/technology/fastpharming
all funds that are holding $ibio https://www.holdingschannel.com/bystock/?symbol=ibio
https://www.ibioinc.com
https://www.ibioinc.com/technology/fastpharming
all funds that are holding $ibio https://www.holdingschannel.com/bystock/?symbol=ibio
During Trumps PR on july 28th, he mentioned "producing 100 million vaccinees as soon as a vaccine is approved and then 500 million doses shortly after"
this is the same approximation that Tom Isett (ceo of $ibio) made in his "The Hill" interview. (the presidents pr, time stamp 0:09 -0:41, )
(tom isletts interview time stamp starts at 9:50 https://thehill.com/homenews/coronavirus-report/509801-coronavirus-report-the-hills-steve-clemons-interviews-thomas
(tom isletts interview time stamp starts at 9:50 https://thehill.com/homenews/coronavirus-report/509801-coronavirus-report-the-hills-steve-clemons-interviews-thomas
and Tom isett talking about BARDA funding.
the BARDA funding budget
President trump goes on to say that "a very very talented general is in charge"; Retired 4 star General James T. Hill is on the board of directors. https://ir.ibioinc.com/board-of-directors
From August 4th to August 11th, an international Share holder by the name of Kenneth B Dart sold off 20% of his 25% stake in $ibio
link to the sec showing Dart selling 20% of his shares. https://www.sec.gov/Archives/edgar/data/1408408/000140840820000050/ecl_ibio13da08132020.htm
link to the sec showing Dart selling 20% of his shares. https://www.sec.gov/Archives/edgar/data/1408408/000140840820000050/ecl_ibio13da08132020.htm
Ken Dart was losing money because of covid so he pulled out of ALL bio-tech https://www.dmagazine.com/frontburner/2020/05/dart-board-gets-first-look-at-covid-budget-blow/
The selling of his shares opens up $ibio for government funding. For those of you that dont know, companies cannot request or receive government funding while an overseas shareholder has a position of 25%. --
-- Who is Ken B Dart, "He is the CEO of the Dart Container Corporation, the inventors of the styrofoam cup. They never patented the machine and process because they didn't want competitors to be able to copy their design. --
- -To this day only a few highly trusted employees of the Dart Container Company are allowed to see the machinery itself." 05/29/15 https://www.bloomberg.com/billionaires/profiles/kenneth-b-dart/
$ibio is using the nicotania benthamiana plant to create its therapeutics and vaccines.
I recently found a study where an IMPROVED strain of Nicotania Benthamiana is used, to my knowledge $ibio has made no updates about the plant they are using, Please note that the study is on Aphid and Whitefly Research and is soley meant to prove existence of an improved strain -
at the end of june, $ibio was given free access to IBM's clinical trial managment. “We are deeply appreciative of IBM’s vote-of-confidence, which recognizes the potential of iBio’s COVID-19 vaccine development efforts from among the hundreds of organizations that applied for -
access to IBM’s ICD solution” said Tom Isett, Co-Chairman & CEO of $ibio. “This technology helps to support the rapid and efficient undertaking of clinical trials of iBio’s COVID-19 vaccine candidates. It also complements our FastPharming System’s core speed, quality and scale-up
advantages in the development of vaccines and therapeutics. Through strategic collaborations like this one, we believe $ibio is now poised with the tools, technology and capital necessary to compete in the fight against COVID-19.” -- $ibio currently anticipates that data from the
- preclinical immunization studies of its two COVID-19 vaccine candidates, IBIO-200 and IBIO-201, which are being conducted at Texas A&M University System laboratories, will be available in Q3-2020. -
Capital Ltd Eastern, a major owner of $ibio, recently acquired 4,440,096 shares of the company. The buys took place at prices ranging from $0.20 to $3.91 per share, on dates ranging from August 07 to August 11, 2020. here's the transcript
http://www.conferencecalltranscripts.org/4/summary/?id=8227821
http://www.conferencecalltranscripts.org/4/summary/?id=8227821
and here are all of iBio's patents https://patents.justia.com/assignee/ibio-inc
and what they have in the pipeline looks promising
and what they have in the pipeline looks promising
their progress with the vaccine and therapeutics can be watched here, https://www.ibioinc.com/therapeutics-and-vaccines#intro
The reason why $ibio dropped from $4.76 on 8/5 to now is that the following Russia Vaccine came out and the rookie bio sector a huge hit, Dart selling most of his shares that he had (25% to 5% remaining), Trump announcing funding for a few companies that have Covid vaccines going
in march, Trump met with executives of pharmaceutical companies to discuss vaccines and the likes, its very interesting to note that 2 of the companies in attendance received funding, who was included in attendance, $ibio is the only company with a single dose vaccine -
also the only company that doesnt have BARDA funding (because they are still on phase 1 of human trials) but they do have a connection to BARDA and DARPA which are major sources of funding for the Bio-tech sector https://stockpence.com/featured/trump-meeting-pharmaceutical-coronavirus/
$ibio, along with
"The Alliance for Biosecurity is a strong, focused, respected, and influential organization. By leveraging our collective knowledge and expertise, the Alliance is committed to building and strengthening the partnerships between government and --
"The Alliance for Biosecurity is a strong, focused, respected, and influential organization. By leveraging our collective knowledge and expertise, the Alliance is committed to building and strengthening the partnerships between government and --
-- the biopharmaceutical industry and to help identify and provide solutions to the threats facing our nation. The Alliance will continue to seek opportunities to influence policy while understanding the political realities." - Christopher Frech, Alliance Chairman, --
-- global government affairs, Emergent BioSolutions
Big shoutout to @itsalibuddy for helping me and doing half the DD that you see, two heads are always better than one.
@TheStocksmen @yatesinvesting @StocksmenFrosty @will_fitz01 @StocksmenShane @StocksmenJussin @StocksmenCARL
@TheStocksmen @yatesinvesting @StocksmenFrosty @will_fitz01 @StocksmenShane @StocksmenJussin @StocksmenCARL
